Jardiance (empagliflozin) / Eli Lilly, Lupin, Boehringer Ingelheim - LARVOL DELTA

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. (PubMed, Cardiovasc Diabetol) - "This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org )."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Diabetic Neuropathy • Genetic Disorders • Heart Failure • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Obstructive Sleep Apnea • Pain • Renal Disease • Respiratory Diseases • Sleep Disorder • Type 1 Diabetes Mellitus

Boldly Bradycardic: A Case Report of Brash Syndrome in the Setting of HFpEF (ATS 2025) - "Her home medication list included carvedilol, spironolactone, furosemide, empagliflozin, exogenous potassium, and recently prescribed ertugliflozin...ACLS protocol was initiated for hypotension, including one round of epinephrine...Standard hyperkalemia treatments of calcium, insulin, and albuterol are effective if BRASH is caught early enough. AV-blocking agents and medications that increase the risk of hyperkalemia should be avoided to prevent recurrence."

Case report • Clinical • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Fatigue • Gastrointestinal Disorder • Hypertension • Hypotension • Immunology • Metabolic Disorders • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

New Triple Therapy in Newly Diagnosed Type 2 Diabetes (clinicaltrials.gov) - P3 | N=296 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Presentation of Euglycemic DKA Precipitated by Paraganglioma (ENDO 2025) - "Due to insurance issues, she had stopped her diabetes regimen of Jardiance and Ozempic eight months prior...Doxazosin was titrated to 2 mg twice a day, and Metoprolol XL 25 mg was added for beta blockade to optimize for surgery... This is the first reported case documenting a presentation of euglycemic DKA triggered by a paraganglioma. The patient had discontinued her SGLT-2 inhibitor and had no other etiology for the disease trigger. Excessive normetanephrines can contribute to lipolysis and impaired pancreatic beta cell function, leading to euglycemic DKA.*."

Cardiovascular • CNS Tumor • Diabetes • Endocrine Cancer • Endocrine Disorders • Hypertension • Metabolic Disorders • Oncology • Pain • Solid Tumor • Type 2 Diabetes Mellitus • SSTR

EMPA-HEART-3: SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure (clinicaltrials.gov) - P3 | N=410 | Not yet recruiting | Sponsor: Subodh Verma

New P3 trial • Cardiovascular • Heart Failure

Comparing Medicare Maximum Fair Prices with Other Drug Prices in Other Countries (ISPOR 2025) - "Approximate monthly costs were calculated and compared between the countries. The comparison showed that the costs of the 10 drugs included in the Part D negotiations (Januvia, Fiasp/NovoLog/NovoRapid insulin products, Farxiga/Forxiga, Enbrel, Jardiance, Xarelto, Eliquis, Entresto, Stelara, and Imbruvica) were still lower in other countries even after price negotiations. Despite substantial discounts provided by Medicare price negotiations, US maximum fair prices remain generally higher than prices applied in other countries with high healthcare spending per capita. A limitation of the analysis is the approximation of monthly drug costs without utilization data."

Medicare • Reimbursement • US reimbursement

SGLT2 inhibitors Use in Kidney Disease: What Did We Learn? (PubMed, Am J Physiol Endocrinol Metab) - "Post marketing cardiovascular outcome trials (CVOT) have demonstrated improved cardiovascular outcomes with use of sodium-glucose cotransporter-2 inhibitors SGLT2i) like canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin in patients with type 2 diabetes mellitus (T2DM), Similarly, secondary analysis of CVOT and renal outcome trials with the use of SGLT2i in patients without T2DM showed improved renal function and albuminuria. Based on our research of published literature, we present a review and propose, consideration of SGLT2i in non-diabetic kidney disease for long term cardiovascular and renal benefit (1). We will highlight relevant translational studies to propose a possible cell-based mechanism for cardiovascular benefits noted secondary to use of SGLT2i."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

The effect of empagliflozin and sitagliptin as an add-on therapy to metformin in blood pressure reduction in diabetic patients in primary health care settings in Riyadh, Saudi Arabia. (PubMed, J Family Med Prim Care) - "Patients had a confirmed diagnosis of T2DM, were prescribed either Janumet or Synjardy, and had at least one BP reading within 3 months before and 2-24 weeks after starting treatment. Although neither drug significantly impacted BP, both combinations reduced HbA1c. Further research with a larger sample is needed to clarify their effects on BP."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Map of the Lipid-Metabolite-Protein Network to Aid Multi-Omics Integration. (PubMed, Biomolecules) - "Furthermore, we used the network to analyze empagliflozin's temporal effects on lipid metabolism...Our framework offers a versatile tool for hypothesis generation, functional analysis, and biomarker discovery. By bridging molecular layers, this approach advances our understanding of disease mechanisms and therapeutic effects, with broad applications in computational biology and precision medicine."

Biomarker • Journal • Cardiovascular • Metabolic Disorders

Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes and Preserved Insulin Secretion on Empagliflozin. (PubMed, Intern Med) - "This report describes the case of a 77-year-old male with type 2 diabetes mellitus on an SGLT2 inhibitor who developed EDKA just after undergoing percutaneous coronary intervention following acute myocardial infarction, with only one day of fasting, despite sufficient insulin secretion. Our case report provides valuable insights into the mechanism and management of SGLT2 inhibitor-associated EDKA in urgent clinical settings."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Empagliflozin-Pretreated MSC-Derived Exosomes Enhance Angiogenesis and Wound Healing via PTEN/AKT/VEGF Pathway. (PubMed, Int J Nanomedicine) - "EMPA-pretreated MSC-derived exosomes effectively enhance angiogenesis and accelerate diabetic wound healing by activating the PTEN/AKT/VEGF signaling pathway. This strategy offers a promising approach for improving diabetic wound repair and provides a potential new therapeutic avenue in regenerative medicine."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • PTEN

Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease. (PubMed, J Cardiovasc Pharmacol) - "Patients with PAD are likely to see improved outcomes and favorable safety with SGLT-2is, namely, canagliflozin, empagliflozin, and dapagliflozin. Literature supports the safe and effective use of SGLT-2is in patients with concomitant PAD, regardless of the indication for use. Ongoing studies are needed to assess specific PAD outcomes with SGLT-2is and determine the specific mechanisms proposed for such benefits."

Journal • Cardiovascular • Peripheral Arterial Disease

Real-World Utilization of Glucagon-Like Peptide-1 Receptor Agonists in Overweight and Obese US Adults (ISPOR 2025) - "Sodium-glucose cotransporter-2 inhibitors were used among 16.5% of all patients, with empagliflozin the most commonly utilized. Based on the AnswerY database, liraglutide was the most used GLP-1 RA for patients with and without diabetes. Based on the AnswerY database, liraglutide was the most used GLP-1 RA for patients with and without diabetes. AnswerY found that BMI appeared to have little effect on real-world GLP-1 RA utilization. GLP-1 RA utilization is high, though dulaglutide usage in patients without diabetes suggests potential off-label usage."

Clinical • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders • Obesity • Sleep Disorder • Type 2 Diabetes Mellitus

The Clinical Impact of Discontinuation of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2is): A Targeted Literature Review (ISPOR 2025) - "In the post-hoc analysis, by 30-days post-withdrawal, the HR (95%CI) for hospitalization for heart failure (HF) or cardiovascular (CV) mortality was 1.18 (95%CI 0.78-1.80) for patients discontinuing empagliflozin (SGLT2i) vs. placebo... Evidence is emerging characterizing the clinical risks following SGLT2i discontinuation. Interruptions in patient access, including due to formulary decisions, must be weighed against the potential for severe complications."

Clinical • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Patient-Reported Outcome Endpoint Emulation in Heart Failure External Control Arm Study (EMULATE-HF PRO-ECA Study) (ISPOR 2025) - "Adults with heart failure (HF) aged ≥18 years with ejection fraction >30% to < 55% and N-terminal-pro-brain natriuretic peptide ≥ 600 pg/ml on empagliflozin or placebo were eligible for inclusion... We successfully replicated the evaluation of a PRO endpoint in an ECA study. Challenges and lessons learned will be used to formulate requirements for relevant ECA data sources and propose best practices. Ensuring robust strategies for the collection, quality, validation, and analysis of PRO data in ECA studies is crucial for the interpretation of findings."

Clinical • Patient reported outcomes • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • NPPB

Exploring the Potential Health Economic Value of the Aldosterone Synthase inhibitor and Sodium Glucose Transporter 2 inhibitor Combination in Chronic Kidney Disease (ISPOR 2025) - P2, P3 | "The simulation modeling suggests the vicadrostat+empagliflozin combination may offer a promising new option in CKD treatment with meaningful cost savings for health systems through improved patient outcomes and avoidance of complications. Clinical outcomes of the ongoing phase 3 trial (EASi-KIDNEY™, NCT06531824) will be essential to confirm these findings."

HEOR • Chronic Kidney Disease • Nephrology • Renal Disease

Empagliflozin for urinary supersaturation reduction in non-diabetic patients with calcium and uric acid kidney stones (SWEETSTONE) (ERA 2025) - No abstract available

Clinical • Late-breaking abstract • Metabolic Disorders • Nephrology • Renal Calculi

IMPACT OF ACUTE EGFR DIPS AND MARKERS OF DISEASE SEVERITY ON EFFECTS OF EMPAGLIFLOZIN ON ACUTE KIDNEY OUTCOME (ERA 2025) - No abstract available

Late-breaking abstract • Nephrology • EGFR

THE CONFIDENCE TRIAL: EFFICACY/SAFETY OF COMBINING FINERENONE WITH EMPAGLIFLOZIN IN PEOPLE WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES (ERA 2025) - No abstract available

Clinical • Late-breaking abstract • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Vicadrostat with and without empagliflozin reduces albuminuria across KDIGO risk class in chronic kidney disease (ERA 2025) - No abstract available

Chronic Kidney Disease • Nephrology • Renal Disease

Effect of Dapagliflozin and Empagliflozin on Phosphate-FGF23 Homeostasis in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis (ERA 2025) - No abstract available

Retrospective data • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • FGF23

The effects of early or late Empagliflozin, Liraglutide & combined therapy on the a-Klotho/Autophagy pathway in renal and pancreatic-ß cells in diabetic db/db mice model. (ERA 2025) - No abstract available

Preclinical • Renal Disease

IMPACT OF DIABETES, ALBUMINURIA, ACUTE EGFR DIP, AND DISEASE SEVERITY ON THE EFFECTS OF EMPAGLIFLOZIN ON PROGRESSION OF CHRONIC KDINEY DISEASE. (ERA 2025) - No abstract available

Diabetes • Metabolic Disorders • Renal Disease • EGFR

Effects of vicadrostat with and without empagliflozin in people with chronic kidney disease by baseline BMI (ERA 2025) - No abstract available

Chronic Kidney Disease • Nephrology • Renal Disease

The effects of empagliflozin on fluid and eletrolyte balance (ERA 2025) - No abstract available

Chronic Kidney Disease • Nephrology • Renal Disease